Table 3.
ICU management and outcome data
| Variables | |
|---|---|
| VZV-related treatment | |
| Aciclovir | 102 (100%) |
| Aciclovir dose, mg/8 h | 10 (10–10) |
| Steroids | 10 (10%) |
| Immunoglobulins | 1 (1%) |
| Systemic antibiotics at ICU admission | 62 (61%) |
| Primary source of bacterial co-infection (n = 40, 39%) | |
| Lung | 24 (60%) |
| Bloodstream | 8 (20%) |
| Skin | 4 (10%) |
| Other | 4 (10%) |
| Life-sustaining therapies | |
| Non-invasive mechanical ventilation | 29 (28%) |
| Invasive mechanical ventilation | 52 (51%) |
| Vasopressors | 36 (35%) |
| Renal replacement therapy | 24 (24%) |
| ARDS criteria according to the Berlin definition (n = 42, 41%) | |
| Mild ARDS | 8 (19%) |
| Moderate ARDS | 10 (24%) |
| Severe ARDS | 24 (57%) |
| Other interventions | |
| Neuromuscular blockers | 26/52 (50%) |
| Prone positioning | 14/52 (28%) |
| Veno-venous ECMO | 7/52 (13%) |
| Outcome data | |
| ICU length of stay (days) | 8 (4–16.75) |
| Hospital length of stay (days) | 14 (9–33) |
| ICU mortality | 17 (17%) |
| Hospital mortality | 24 (24%) |
Values are shown as n (%) or median (25th–75th percentiles)
AKI acute kidney injury, ARDS acute respiratory distress syndrome, ECMO extra-corporeal lung oxygenation, ICU intensive care unit, VZV varicella-zoster virus